Method to predict response to pharmacological chaperone treatment of diseases
AssigneeAmicus Therapeutics, Inc.
InventorsElfrida Benjamin, Hung V. Do, Xiaoyang Wu, John Flanagan, Brandon Wustman
Life of this patent
Estimating the term…
Abstract
The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.
Claims44
A method for determining whether a patient expressing a mutant form of a protein will respond to treatment with a specific pharmacological chaperone for the protein, which method comprises
- a. contacting a first host cell with a pharmacological chaperone specific for the protein, wherein the first host cell expresses the mutant form of the protein;
- and
- b. comparing protein activity in a second host cell not contacted with the specific pharmacological chaperone, with protein activity in the first host cell contacted with the specific pharmacological chaperone,
- wherein an increase in protein activity in the first host cell contacted with the specific pharmacological chaperone compared to the activity of the protein expressed by the second host cell not contacted with the specific pharmacological chaperone indicates that the patient will respond to treatment with the specific pharmacological chaperone.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for producing a treatment therapy table, wherein the treatment therapy table indicates if a specific pharmacological chaperone is an effective compound for increasing the activity of a mutant protein, which method comprises:
- a. contacting a first host cell with a pharmacological chaperone specific for the protein, wherein the first host cell expresses the mutant protein;
- b. comparing protein activity in the first host cell contacted with the specific pharmacological chaperone with protein activity in a second host cell, wherein the second host cell expresses the mutant protein and is not contacted with the specific pharmacological chaperone;
- and
- c. recording the result of step (b) in the treatment therapy table,
- wherein a specific pharmacological chaperone recorded in the treatment therapy table that increases the activity of the mutant protein in the first host cell compared to the activity of the mutant protein in the second cell is a specific pharmacological chaperone that can be used as a therapy for a patient who expresses the mutant protein.
(canceled)
(canceled)
(canceled)
(canceled)
A method of selecting a specific pharmacological chaperone for treating a patient expressing a mutant form of a protein,
- wherein the Specific Pharmacological Chaperone is selected from a treatment reference table which comprises a list of mutations in the protein and the effect of the specific pharmacological chaperone on the activity of the protein mutations, and
- wherein the Specific Pharmacological Chaperone selected for treating the patient increases the activity of the mutant protein expressed by the patient.
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a patient diagnosed with Fabry disease which comprises administering to the patient a therapeutically effective dose of 1-deoxygalactonorjirimycin, wherein the patient expresses a mutant α-galactosidase A selected from the group consisting of the α-galactosidase A mutations A121T, A156V, A20P, A288D, A288P, A292P A348P, A73V, C52R, C94Y, D234E, D244H, D264Y, E338K, E341D, E398K, E48K, F113L, G144V, G260A, G271S, G328A, G35R, G373D, G373S, H225R, I219N, I242N, I270T, I303N, I317T, I354K, L14P, L166V, L243F, L300F, L310F, L32P, M267I, M284T, M296I, M72V, M76R, N224S, N298K, N298S, N320I, N34K, P259L, P265L, P265R, P293A, P293S, P409S, P40L, Q279H, Q279R, Q280H, Q280K, Q312H, Q321E, Q321R, Q327E, R301P, R363H, R49G, R49S, S201Y, S276N, S297C, S345P, T194I, V269M, W340R, W47L, and W95S.
(canceled)
A method for treating a patient who expresses a mutant protein comprising identifying the mutant protein, determining if the patient should respond to a specific pharmacological chaperone using a treatment therapy table, and if it is determined that the patient should respond to said specific pharmacological chaperone, administering said specific pharmacological chaperone to the patient.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.